Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: Systemic review and meta-analysis

[1]  Fares Alahdab,et al.  Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis. , 2019, The Journal of clinical endocrinology and metabolism.

[2]  Iqra Qamar,et al.  Role of Bisphosphonate Therapy in Patients with Osteopenia: A Systemic Review , 2019, Cureus.

[3]  J. Cauley,et al.  Change in Bone Density and Reduction in Fracture Risk: A Meta‐Regression of Published Trials , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  D. Solomon,et al.  Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. , 2018, The Journal of clinical endocrinology and metabolism.

[5]  I. Reid,et al.  Fracture Prevention with Zoledronate in Older Women with Osteopenia , 2018, The New England journal of medicine.

[6]  Qingsheng Zhang,et al.  Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis , 2018, Journal of Orthopaedic Surgery and Research.

[7]  M. Phipps,et al.  Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[8]  Zongqiang Wang,et al.  A network meta‐analysis on the short‐term efficacy and adverse events of different anti‐osteoporosis drugs for the treatment of postmenopausal osteoporosis , 2018, Journal of cellular biochemistry.

[9]  A. Grauer,et al.  Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study. , 2017, Bone.

[10]  I. Reid,et al.  Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial , 2017, Canadian Medical Association Journal.

[11]  X. Qi,et al.  The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment , 2017, Bone & joint research.

[12]  A. Qaseem,et al.  Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. , 2017, Annals of internal medicine.

[13]  L. Sànchez-Riera,et al.  Fragility Fractures & Their Impact on Older People. , 2017, Best practice & research. Clinical rheumatology.

[14]  V. Gudnason,et al.  Imminent risk of fracture after fracture , 2017, Osteoporosis International.

[15]  Yu-sheng Li,et al.  Network Meta-Analysis of Pharmacological Agents for Osteoporosis Treatment and Fracture Prevention , 2016, Cellular Physiology and Biochemistry.

[16]  S. Zhai,et al.  Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses , 2016, Osteoporosis International.

[17]  R. Eastell,et al.  Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia , 2016, Osteoporosis International.

[18]  J. Shen,et al.  Influences of teriparatide administration on marrow fat content in postmenopausal osteopenic women using MR spectroscopy , 2016, Climacteric : the journal of the International Menopause Society.

[19]  Dongbao Zhao,et al.  Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis , 2015, Menopause.

[20]  N. Binkley,et al.  Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial , 2014, Osteoporosis International.

[21]  Cesar Libanati,et al.  Romosozumab in postmenopausal women with low bone mineral density , 2014, The New England journal of medicine.

[22]  I. Reid,et al.  Duration of Antiresorptive Effects of Low‐Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo‐Controlled Trial , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  E. Vittinghoff,et al.  BMD changes and predictors of increased bone loss in postmenopausal women after a 5‐year course of alendronate , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  D. Felsenberg,et al.  Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT. , 2012, Bone.

[25]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[26]  J. Ioannidis,et al.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.

[27]  E. Eriksen.  Treatment of osteopenia , 2011, Reviews in Endocrine and Metabolic Disorders.

[28]  E. Siris,et al.  Primary Care Use of FRAX®: Absolute Fracture Risk Assessment in Postmenopausal Women and Older Men , 2010, Postgraduate medicine.

[29]  C. Benhamou,et al.  Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass: A Randomized Controlled Trial , 2009, Obstetrics and gynecology.

[30]  I. Reid,et al.  The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. , 2009, The Journal of clinical endocrinology and metabolism.

[31]  J. S. San Martin,et al.  Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. , 2008, The Journal of clinical endocrinology and metabolism.

[32]  A. Grauer,et al.  Effects of risedronate on fracture risk in postmenopausal women with osteopenia , 2007, Osteoporosis International.

[33]  S. Jamal,et al.  Low bone mineral density and fracture burden in postmenopausal women , 2007, Canadian Medical Association Journal.

[34]  P. Miller,et al.  Denosumab in Postmenopausal Women with Low Bone Mineral Density , 2007 .

[35]  C. Christiansen,et al.  The effect on bone mass and bone markers of different doses of ibandronate — A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-finding study , 2006, Osteoporosis International.

[36]  M. Nevitt,et al.  Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. , 2005, Mayo Clinic proceedings.

[37]  O. Johnell,et al.  Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. , 2003, Bone.

[38]  B. Stuckey,et al.  Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. , 2003, Archives of internal medicine.

[39]  Jacques P. Brown,et al.  Intravenous zoledronic acid in postmenopausal women with low bone mineral density. , 2002, The New England journal of medicine.

[40]  P Geusens,et al.  Risk of new vertebral fracture in the year following a fracture. , 2001, JAMA.

[41]  M. Yen,et al.  Effects of alendronate on osteopenic postmenopausal Chinese women. , 2000, Bone.

[42]  B. Walsh,et al.  Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. , 2000, The Journal of clinical endocrinology and metabolism.

[43]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[44]  A. Phillips.  The Fracture Intervention Trial , 1997, The Lancet.

[45]  C. Christiansen,et al.  The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study , 1996 .

[46]  N. Ghannam,et al.  Book review: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. , 1994, Annals of Saudi medicine.

[47]  Claus Christiansen,et al.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. , 1994, World Health Organization technical report series.